Tobramycin (Nebcin)

Subscribe to Selected New Research on Tobramycin

1236 relevant articles (202 outcomes, 208 trials/studies) found for this Drug

Description: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.

Also Known As:

Nebcin; Brulamycin; Nebicin; Obracin; Tobracin; Tobramycin Sulfate; Sulfate, Tobramycin; Nebramycin Factor 6; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-

Relationship Network

Drug Context: Research Results

Carbohydrates: 2949

Glycosides: 342

Aminoglycosides: 1078

Kanamycin: 678

Nebramycin

Tobramycin: 1236

2''-(adenosine-5'-phosphoryl)tobramycin

2''-(adenosine-5'-thiophosphoryl)tobramycin

6''-O-carbamoyltobramycin

6'-N-4-azidobenzyltobramycin

6'-N-acetyltobramycin

Experts

1.	Konstan, Michael W: 4 articles (07/2007 - 03/2003)
2.	Smyth, Alan: 4 articles (07/2006 - 05/2002)
3.	Tan, Kelvin H-V: 4 articles (07/2006 - 05/2002)
4.	Ratjen, Felix: 3 articles (08/2008 - 06/2007)
5.	Ratjen, F: 3 articles (07/2008 - 09/2001)
6.	Nikolaizik, W H: 3 articles (07/2008 - 09/2001)
7.	Burns, Jane L: 3 articles (07/2007 - 01/2002)
8.	Geller, David E: 3 articles (04/2007 - 07/2002)
9.	Hyman-Taylor, Pauline: 3 articles (07/2006 - 05/2002)
10.	Stableforth, David: 3 articles (07/2006 - 02/2005)

Related Diseases

1.	Infection 07/01/2007 - "CONCLUSION: As opposed to normal saline irrigations, topical tobramycin led to a significant improvement in the degree of infection within an animal model of P" 04/01/2007 - "We evaluated the pharmacokinetics (PK) and safety of tobramycin inhalation powder (TIP), a novel dry-powder formulation designed to deliver a high payload of tobramycin topically to the lungs for management of chronic Pseudomonas aeruginosa infections" 09/01/1981 - "The infection was cured more frequently in patients who achieved a high ratio between the peak serum concentration of tobramycin and the minimal inhibitory concentration of tobramycin against the pathogenic organism (so-called therapeutic ratio)" 11/01/1996 - "It is concluded that intratracheal instillation of surfactant-tobramycin is superior to tobramycin alone in protecting animals from death due to a respiratory Klebsiella pneumoniae infection." 05/01/1976 - "Tobramycin was effective for selected gram negative bacillary infections and particularly for P" Order ALL the reference details at left...
2.	Cystic Fibrosis (Mucoviscidosis) 01/01/2007 - "BACKGROUND: Delivery of tobramycin by inhalation to the lungs of patients with cystic fibrosis (CF) who are infected with Pseudomonas aeruginosa has been proven to be effective and safe" 01/01/2000 - "Phase III trials of the aerosolized delivery of tobramycin to cystic fibrosis (CF) patients demonstrated a significant improvement in pulmonary function and in sputum bacterial density" 03/15/2003 - "We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis." 04/01/2002 - "In a previously published placebo-controlled trial, tobramycin solution for inhalation (TSI) was shown to improve lung function and other outcomes in patients with cystic fibrosis (CF)" 05/01/2001 - "Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study." Order ALL the reference details at left...
3.	Keratitis 01/01/1978 - "We evaluated several therapeutic modifications in an attempt to improve efficacy of topical therapy with tobramycin of experimental Pseudomonas keratitis in guinea pigs" 05/01/1987 - "Finally, a Pseudomonas aeruginosa keratitis model in the rat demonstrates the antibiotic efficacy of topical tobramycin treatment over untreated controls (P less than 0.00001), and a progressively enhanced efficacy with increasing tobramycin concentrations is suggested" 05/01/1979 - "We determined the efficacy of tobramycin administered by topical, intramuscular, and subconjunctival routes in guinea pigs and rabbits with experimental Pseudomonas keratitis" 07/01/2001 - "The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis." 02/01/2000 - "Tobramycin-responsive Fusarium oxysporum keratitis." Order ALL the reference details at left...
4.	Sepsis (Septicemia) 07/01/1986 - "Tobramycin therapy for lethal sepsis in the dog." 09/01/1984 - "Five clinical strategies for monitoring serum tobramycin concentrations were compared in a population of children and young adults with normal renal function receiving tobramycin for suspected sepsis" 05/01/1983 - "Intramuscular injections of tobramycin and subcutaneous injection of vaccine also prevented development of sepsis due to Ps" 01/01/1994 - "Its antimicrobial spectrum and bactericidal activity make tobramycin an appropriate agent for treatment of sepsis caused by gram-negative bacteria and its lack of propensity to elicit excessive release of endotoxin may avoid exacerbation of endotoxin-related shock in sepsis." 01/01/1992 - "Six of eight rabbits receiving IM tobramycin had wound infections, and five of five in whom non-antibiotic-containing beads had been implanted had significant wound infections, with one of the five dying of sepsis on the 3rd day of the experiment" Order ALL the reference details at left...
5.	Pneumonia (Pneumonitis) 01/22/2000 - "OBJECTIVE: The aim of this study was to assess renal and respiratory tolerance of aerosolized tobramycin in intubated and mechanically ventilated patients with nosocomial pneumonia" 03/01/1999 - "OBJECTIVE: To study the penetration of tobramycin in lung tissue evaluated as the concentration in epithelial lining fluid and to characterize the time course of the drug in the treatment of patients with pneumonia" 05/01/2006 - "In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin." 01/22/2000 - "CONCLUSION: Aerosolized tobramycin was well tolerated in ventilated patients with documented nosocomial pneumonia." 03/01/1999 - "METHODS: The subjects were 16 patients with pneumonia and taking tobramycin who had clinical indications for bronchoscopy" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Gentamicins (Gentamicin)
2.	Ciprofloxacin (Cipro)
3.	Ceftazidime (Fortum)
4.	Clindamycin (Cleocin)
5.	Amikacin (A.M.K)
6.	Anti-Bacterial Agents (Antibiotics)
7.	Cefotaxime (Kendrick)
8.	Cefazolin (Ancef)
9.	Aminoglycosides
10.	Piperacillin

Related Therapies and Procedures

1.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
2.	Intensive Care (Surgical Intensive Care)
3.	Phacoemulsification
4.	Artificial Respiration (Mechanical Ventilation)
5.	Debridement

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 13883 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>